GlassScriptPhysician profile
Samantha Dimeo
NPI 1841840071
$3,034.47
in general payments reported to CMS, 2019-2025
17 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $344 · 2023: $467 · 2024: $1,011 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279 · Consulting Fee: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.70 |
| Consulting Fee | $685.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,409.29 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $726.34 | 2021-2025 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $153.95 | 2021 | |
| Biogen, INC. | $129.42 | 2021-2025 | Vumerity |
| Neurocrine Biosciences, INC. | $118.51 | 2023-2025 | Ingrezza |
| Argenx US, INC. | $109.20 | 2022-2023 | Vyvgart |
| Pfizer INC. | $104.15 | 2023-2025 | |
| Lilly USA, LLC | $49.23 | 2022-2023 | Amyvid |
| Medtronic, INC. | $44.12 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Averitas Pharma INC. | $43.50 | 2024-2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $30.30 | 2022-2024 | Rytary |
| Grifols USA, LLC | $24.83 | 2025 | Gamunex-C |
| Tg Therapeutics, INC. | $22.71 | 2025 | |
| Genzyme Corporation | $21.80 | 2025 | |
| Grt US Holding, INC. | $16.24 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.13 | 2025 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $14.75 | 2023 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Dimeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.